Myriad Genetics to Present at the Morgan Stanley Healthcare Conference

        Print
| Source: Myriad Genetics, Inc.

SALT LAKE CITY, Aug. 28, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the Morgan Stanley Healthcare Conference at 9:45 a.m. Eastern time on September 10, 2014, at the Grand Hyatt in New York City.

The presentation will be available to interested parties through a live audio webcast accessible through a link on the investor relations section of Myriad's website at www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Media Contact: Ron Rogers
(801) 584-3065


Investor Contact: Scott Gleason
(801) 584-1143